INS and type 2 diabetes mellitus: Given that >60% of participants achieved fasting SMPG targets but only 20% to 30% achieved HbA1c targets, additional treatment intensification with bolus insulin, addition of GLP‐1RA therapy, or other drugs that reduce postprandial glucose peaks may be beneficial in this population with relatively advanced T2DM (mean duration of diabetes of 13 years); however, the suboptimal HbA1c target achievement in Take Control may be related to the higher fasting SMPG target (4.4‐7.2 mmol/L) compared with the EDITION programme (4.4‐5.6 mmol/L).22